Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
15.25
-0.05 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 4D Molecular Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
$50M Bet On Coinbase Global? Check Out These 4 Stocks Insiders Are Buying
May 12, 2023
Although US stocks closed mixed on Thursday, there were a few notable insider trades.
Via
Benzinga
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 11, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 10, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 09, 2023
Underwriters’ full exercise of option brings gross proceeds to $138.0 million
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for 4D Molecular Therapeutics
April 13, 2023
Via
Benzinga
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
May 04, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
May 04, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
SVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Know
April 13, 2023
Via
Benzinga
Expert Ratings for 4D Molecular Therapeutics
March 16, 2023
Via
Benzinga
Analyst Ratings for 4D Molecular Therapeutics
January 30, 2023
Via
Benzinga
What's Going On With 4D Molecular Therapeutics Stock Today
April 27, 2023
4D Molecular Therapeutics (NASDAQ: FDMT) shares are trading lower after the company released interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM trial for wet...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 27, 2023
Via
Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
Dow Surges 100 Points; Meta Platforms Reports Upbeat Results
April 27, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.38% to 33,429.66 while the NASDAQ rose 0.88%...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 27, 2023
Via
Benzinga
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
April 27, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
April 24, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
April 13, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks Sitting in the Sweet Spot
March 24, 2023
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.
Via
InvestorPlace
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
March 15, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study
February 23, 2023
Via
Benzinga
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
February 22, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
February 16, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
February 02, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
January 30, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
January 09, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
How Is The Market Feeling About 4D Molecular Therapeutics?
December 15, 2022
4D Molecular Therapeutics's (NASDAQ:FDMT) short percent of float has fallen 15.19% since its last report. The company recently reported that it has 2.29 million shares sold short, which is 8.82% of all...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.